CannaMD

MARCH 26, 2024

As the DEA considers this recommendation, a new era of research, medical therapy, and broader societal acceptance of marijuana seems on the horizon, promising substantial changes in how cannabis is perceived and utilized.

DEA

Cannabis Law Report

OCTOBER 4, 2021

Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy

Cannabis Law Report

MARCH 18, 2022

Husch Blackwell has launched its Psychedelics and Emerging Therapie s team, an interdisciplinary, cross-office group of lawyers capable of addressing the challenges faced by innovators that seek to research, develop and commercialize novel therapies based on psychedelic drugs. By Steve Levine & Marshall Custer. March 18, 2022.

Therapy

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA

Veriheal

FEBRUARY 23, 2024

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.

DEA

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? .

DEA

Veriheal

APRIL 11, 2022

Drug Enforcement Agency (DEA). I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

Pharmaceutical

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law

CannaMD

NOVEMBER 20, 2020

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. If you think that’s crazy, consider this: Marijuana – which has been referred to as a “gateway drug” for decades – has recently been deemed “a promising adjunct therapy for the treatment of cocaine dependence.”

Therapy

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. In contrast, it is unclear to what extent people most in need of psychedelic therapies will benefit. So far, that’s questionable.

Law

Veriheal

AUGUST 24, 2022

Any sales of psychedelic compounds would still be strictly prohibited; however, the initiative would allow for people to offer psychedelic services such as guidance and therapy or for harm reduction or spiritual purposes with or without payment. Not all alternative medicine advocates are in support of the Natural Medicine Health Act, however.

Legalization

NewsMunchies

NOVEMBER 12, 2021

State-level ballot measures may further broaden the legal circumstances and settings in which psychedelics can be used for mental health therapy. The problem is, under federal law, psilocybin remains a prohibited Schedule 1 Drug, defined by the DEA as having “no currently accepted medical use and a high potential for abuse.”

Clinical Trials

Cannabis Law Report

SEPTEMBER 12, 2021

Department of Agriculture) website and look at the laboratories that the DEA (Drug Enforcement Administration) has approved as being appropriate for analysis of hemp crops,” Dr. Boothe said. “If you’re looking for a product that has a certificate of analysis that you can have faith in—as I would—go to the USDA (U.S.

Patients

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear.

CBD

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,

Clinical Trials

Veriheal

DECEMBER 27, 2022

Scientists Hope New Findings Will Help Expand Research on Psychedelic Therapy. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development

Cannabis Law Report

OCTOBER 6, 2021

Bright Green will be operating under a Memorandum of Agreement with the Drug Enforcement Administration (DEA). Today launches a new era in plant-based therapy research. According to a press release by the company, they intend for the facility to be part of a larger national market for cannabis research and products.

DEA

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine

MedicalJane

JUNE 29, 2018

. “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.” The Next Move Is On The DEA. Epidiolex’s launch is in the hands of the DEA. ” –FDA Commissioner Scott Gottlieb.

Clinical Trials

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects were randomly divided into two groups, each of which received three individual sessions of talk therapy. Image via. View original article.

Clinical Trials

Medical Marijuana Program Connection

MARCH 2, 2023

® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® Read More

DEA

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. The safety and efficacy of MDMA-assisted therapy is currently under investigation. MEDIA CONTACT .

Clinical Trials

SpeedWeed

MARCH 28, 2021

MAPS has been trying to get approved for a cultivation license for almost 20 years and filed a lawsuit in December 2020 against the DEA. In the lawsuit, MAPS stated the DEA has failed to process more than 30 outstanding license applications for over 4 years despite administrative guidance.

Clinical Trials

SpeedWeed

AUGUST 16, 2021

During the keynote session titled “Sue’n the DEA: The Story of a Cannabis Research Breakthrough,” Dr. Sisley—a pioneering medical cannabis researcher and volunteer medical director for more than 40 state cannabis licenses—will share her journey on navigating scientific and legal complexities of medical cannabis research.

Media

Sensi Seeds

NOVEMBER 28, 2018

Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.) As a result, GW’s latest CBD product, EPIDIOLEX ® was entered into the Spanish pharmacopeia over the summer.

CBD

Cannabis Law Report

OCTOBER 5, 2021

“This shows that combination of psilocybin and music has a strong emotional effect, and we believe that this will be important for the therapeutic application of psychedelics if they are approved for clinical use,” said lead researcher Dea Siggaard Stenbæk , Associate Professor University of Copenhagen.

Clinical Trials

MedicalJane

JUNE 29, 2018

Doctors may not prescribe cannabis products to patients because marijuana is currently listed as an example of a Schedule I drug according to the DEA. How much advice and direction are you able to give about using cannabis to help reach the ultimate goal of my therapy, e.g., alleviating symptoms like pain or inflammation? .

Patients

Cannabis Law Report

AUGUST 23, 2021

Additionally, the marketing of unapproved treatments by veterinarians increases the likelihood that animal owners may choose to use unapproved products instead of approved therapies to treat serious illnesses in their pets, which could result in worsening of disease and increased animal suffering.

Pets

Cannabis Law Report

NOVEMBER 20, 2021

Drug Enforcement Administration (DEA), the Alabama Prescription Drug Monitoring Program maintained by Alabama Department of Public Health, and the Alabama Medical Cannabis Patient Registry System maintained by the Alabama Medical Cannabis Commission. Obtaining this permit requires the physician to: complete an application. 31 each year.

Patients

SpeedWeed

AUGUST 16, 2021

And we’re gonna have to change therapies to try to win this battle. He owned and operated Eddy’s Medicinal Gardens and Multi-Denominational Chapel of Cannabis and Rastafari, which was raided by Drug Enforcement Administration (DEA) officials on August 18, 2004—the 17th anniversary of which is just days away.

DEA

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. Breakthrough Therapy status obtained by COMPASS Pathways and Usona Institute. Breakthrough Therapy.

Clinical Trials

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY.

Clinical Trials

Canna Care Docs

SEPTEMBER 26, 2019

An open-minded approach toward alternative therapies Possess an active Connecticut medical license issued by the Connecticut Department of Public Health. Possess an active controlled substance registration issued by the Connecticut Department of Consumer Protection that is not subject to limitation.

History

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” Once consumed—whether fresh or dried in the form of a brewed tea or an edible—this hallucinogenic chemical transforms into psilocin.

Research and Development